Michelle Levy, MD
Medical Oncologist / Hematologist
About Michelle Levy, MD
Dr. Levy is a board-certified medical oncologist and hematologist specializing in malignant and benign hematology. She treats blood cancers including leukemia, multiple myeloma, Non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma.
Dr. Levy also treats patients with benign blood disorders including clotting, bleeding, hereditary and pregnancy-related conditions as well as hemochromatosis, iron deficiency, anemia, thrombocytopenia. In addition, she performs surgical clearances.
She participates in a bi-monthly city-wide hematology tumor board to review complex cases and collaborate on patient care with other blood cancer experts and discuss patient treatment options. Dr. Levy practices evidence-based medicine and follows National Comprehensive Cancer Network (NCCN) guidelines.
Clinical Care Expertise
- Benign Hematology
- Bleeding Disorders
- Bone Marrow Biopsy
- Clotting Disorders
- Hereditary Hemochromatosis
- Hodgkin's Lymphoma
- Iron Deficiency
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML)
- Malignant Hematology
- Medical Oncology
- Multiple Myeloma
- Monoclonal Gammopathy (MGUS)
- Smoldering Multiple Myeloma
- Myeloid Malignancies
- Myeloproliferative Neoplasms
- Polycythemia Vera
- Essential Thrombocytosis
- Primary Myelofibrosis
- Myelodysplastic Syndromes
- Non-Hodgkin's Lymphoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Peripheral T-Cell Lymphoma and Other T-Cell Lymphomas
- Pregnancy-Related Blood Disorders
- Surgical Clearances
Hematology & Oncology, Penn State Hershey Medical Center, Hershey, PA
Internal Medicine, Kaiser Permanente Medical Center, Santa Clara, CA
Emory University School of Medicine, Atlanta, GA
Patient Care Philosophy
My goal is to provide my patients with a compassionate whole-person approach to care. I take the time to listen to my patients and understand their needs, concerns, and goals. I focus on educating my patients and their families, such that they can truly understand their diagnosis and feel confident in the plan of care.
American Society of Clinical Oncology
American Society of Hematology
Levy MA, Claxton DF. “Therapeutic inhibition of BCL-2 and related family members.” Expert Opin Investig Drugs. 2017;26(3):293-301.
Michelle Levy; Liisa Lyon; Erika Barbero; John Wong; Jennifer Marie Suga; Danny Sam; Minggui Pan. “Histologic Grade is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.” Med Sci (Basel). 2017 Dec 11;5(4):34.
Pu, J. J., Ehmann, W. C., Liao, J., Capper, C., Levy, M., Claxton, D. F., Rybka, W. B., Hohl, R. J., & Epner, E. M. (2016). “The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma.” Blood, 128(22), 1792.
Levy M.A.; Carrasquillo, Y.; Drobish, J.; Alter, B.J.; Gereau, R.W. “Group I mGluRs activate ERK signaling in GABAergic neurons of the central nucleaus of the amygdala and contribute to mechanical hypersensitivity in mice.” Society for Neuroscience Abstracts.